$BRLS
Borealis Foods Inc. Stock $brls

$brls Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-K Financial Statement

#000121390023025396 Filed on March 31, 2023

Income Statement

Concept	2022 Q4	2022	2021
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit		$176.0M	$172.5M
YoY Change		2.0%
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$746.1K	$2.887M	$428.4K
YoY Change	85.71%	573.84%
Operating Profit		-$2.887M	$172.1M
YoY Change		-101.68%
Interest Expense	$1.510M	$2.584M	$3.960K
YoY Change	45095.21%	65154.29%
% of Operating Profit			0.0%
Other Income/Expense, Net		$0.00	$16.79K
YoY Change		-100.0%
Pretax Income	$763.4K	-$302.5K	-$407.6K
YoY Change	-300.05%	-25.78%
Income Tax
% Of Pretax Income
Net Earnings	$763.4K	-$302.5K	-$407.6K
YoY Change	-300.05%	-25.78%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	$0.03	-$0.01	-$18.64K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept	2022 Q4	2022	2021
SHORT-TERM ASSETS
Cash & Short-Term Investments	$680.8K	$680.8K	$1.123M
YoY Change	-39.4%	-39.4%
Cash & Equivalents	$680.8K
Short-Term Investments
Other Short-Term Assets	$236.0K	$236.0K	$312.6K
YoY Change	-24.5%	-24.5%
Inventory
Prepaid Expenses	$236.0K
Receivables
Other Receivables
Total Short-Term Assets	$916.8K	$916.8K	$1.436M
YoY Change	-36.15%	-36.16%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$178.5M	$178.5M	$176.0M
YoY Change	1.47%	1.47%
Other Assets	$0.00	$0.00	$96.25K
YoY Change	-100.0%	-100.0%
Total Long-Term Assets	$178.5M	$178.5M	$176.1M
YoY Change	1.41%	1.41%
TOTAL ASSETS
Total Short-Term Assets	$916.8K	$916.8K	$1.436M
Total Long-Term Assets	$178.5M	$178.5M	$176.1M
Total Assets	$179.4M	$179.4M	$177.5M
YoY Change	1.11%	1.11%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses	$842.5K	$842.5K	$235.1K
YoY Change	258.44%	258.44%
Deferred Revenue
YoY Change
Short-Term Debt	$1.500M	$1.500M	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.501M	$2.501M	$235.1K
YoY Change	964.09%	964.09%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.501M	$2.501M	$235.1K
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$2.501M	$2.501M	$235.1K
YoY Change	964.09%	964.09%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.585M
YoY Change	288.79%
Common Stock	$30.00
YoY Change	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$1.584M	$176.9M	$177.3M
YoY Change
Total Liabilities & Shareholders Equity	$179.4M	$179.4M	$177.5M
YoY Change	1.11%	1.11%

Cashflow Statement

Concept	2022 Q4	2022	2021
OPERATING ACTIVITIES
Net Income	$763.4K	-$302.5K	-$407.6K
YoY Change	-300.05%	-25.78%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$1.439M	-$2.106M	-$602.2K
YoY Change	130.75%	249.69%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	-$176.0M
YoY Change		-100.0%
Cash From Investing Activities	$0.00		-$176.0M
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$0.00	$185.3M
YoY Change		-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.600M	$1.663M	177.7M
YoY Change	-3200100.0%	-99.06%
NET CHANGE
Cash From Operating Activities	-1.439M	-$2.106M	-602.2K
Cash From Investing Activities	0.000		-176.0M
Cash From Financing Activities	1.600M	$1.663M	177.7M
Net Change In Cash	161.0K	-$442.6K	1.123M
YoY Change	-125.82%	-139.4%
FREE CASH FLOW
Cash From Operating Activities	-$1.439M	-$2.106M	-$602.2K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent		usd
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-40778
CY2022	dei	Entity Registrant Name EntityRegistrantName	OXUS ACQUISITION CORP.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	E9
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	300/26
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Dostyk Avenue
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Almaty
CY2022	dei	Entity Address Country EntityAddressCountry	KZ
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	050020
CY2022	dei	City Area Code CityAreaCode	(727)
CY2022	dei	Local Phone Number LocalPhoneNumber	355-8021
CY2022	dei	Security12b Title Security12bTitle	Class A ordinary shares, par value $0.0001 per share
CY2022	dei	Trading Symbol TradingSymbol	OXUS
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2022	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	true
CY2022Q2	dei	Entity Public Float EntityPublicFloat	175851000	usd
CY2022	dei	Auditor Firm AuditorFirmId	688
CY2022	dei	Auditor Name AuditorName	Marcum LLP
CY2022	dei	Auditor Location AuditorLocation	New York, NY
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	680792	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1123384	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	236002	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	312584	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	916794	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	1435968	usd
CY2022Q4	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	178532948	usd
CY2021Q4	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	175953964	usd
CY2021Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	96252	usd
CY2022Q4	us-gaap	Assets Assets	179449742	usd
CY2021Q4	us-gaap	Assets Assets	177486184	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	842513	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	235051	usd
CY2022Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	1500000	usd
CY2022Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	158640	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2501153	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	235051	usd
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	178532948	usd
CY2021Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	175950000	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	30	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	30	usd
CY2022Q4	oxus	Common Stock Value One CommonStockValueOne	431	usd
CY2021Q4	oxus	Common Stock Value One CommonStockValueOne	431	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1708296	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1584820	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-407624	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-1584359	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	1301133	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	179449742	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	177486184	usd
CY2022	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	2886611	usd
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	428376	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-2886611	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-428376	usd
CY2022	oxus	Dividend Received DividendReceived	-2578984	usd
	oxus	Dividend Received DividendReceived	-3964	usd
CY2022	us-gaap	Interest Income Other InterestIncomeOther	4010	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	1073	usd
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	16788	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-302544	usd
	us-gaap	Net Income Loss NetIncomeLoss	-407624	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	1301133	usd
CY2022	us-gaap	Reclassifications Of Temporary To Permanent Equity ReclassificationsOfTemporaryToPermanentEquity	-2582948	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-302544	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-1584359	usd
	oxus	Issuance Of Class B Ordinary Shares To Sponsor IssuanceOfClassBOrdinarySharesToSponsor	25000	usd
	oxus	Stock Issued During Period Value New Issuance Of Underwriter Founder Shares StockIssuedDuringPeriodValueNewIssuanceOfUnderwriterFounderShares	40	usd
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	9276918	usd
	us-gaap	Stock Redeemed Or Called During Period Value StockRedeemedOrCalledDuringPeriodValue	-17847202	usd
	oxus	Adjustments To Additional Paid In Fair Value Of Private Warrants AdjustmentsToAdditionalPaidInFairValueOfPrivateWarrants	10270789	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	-16788	usd
	us-gaap	Net Income Loss NetIncomeLoss	-407624	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	1301133	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-302544	usd
	us-gaap	Net Income Loss NetIncomeLoss	-407624	usd
CY2022	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	2578984	usd
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	3964	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	1073	usd
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-16788	usd
CY2022	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	604049	usd
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	235051	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-76582	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	408836	usd
CY2022	oxus	Increase Decrease In Prepaid Expenses Other Non Current IncreaseDecreaseInPrepaidExpensesOtherNonCurrent	96252	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2105718	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-602161	usd
	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	175950000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-175950000	usd
	oxus	Proceeds From Issuance Of Common Stock Sponsor ProceedsFromIssuanceOfCommonStockSponsor	25000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	40	usd
	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity	175950000	usd
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	9300000	usd
CY2022	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	1500000	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	279935	usd
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	279935	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	7599495	usd
CY2022	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	163126	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1663126	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	177675545	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-442592	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	1123384	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1123384	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	680792	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1123384	usd
	oxus	Deferred Offering Costs Included In Accrued Expenses DeferredOfferingCostsIncludedInAccruedExpenses	32050	usd
	oxus	Issuance Of Underwriter Founder Shares IssuanceOfUnderwriterFounderShares	30	usd
CY2022	oxus	Remeasurement For Class A Ordinary Shares Subject To Redemption RemeasurementForClassAOrdinarySharesSubjectToRedemption	2582948	usd
CY2022Q4	us-gaap	Business Acquisition Cost Of Acquired Entity Transaction Costs BusinessAcquisitionCostOfAcquiredEntityTransactionCosts	3700000	usd
CY2022	us-gaap	Expense Related To Distribution Or Servicing And Underwriting Fees ExpenseRelatedToDistributionOrServicingAndUnderwritingFees	3000000	usd
CY2022Q4	us-gaap	Deferred Costs DeferredCosts	700000	usd
CY2021Q3	us-gaap	Deposits Deposits	153000000	usd
CY2021Q3	oxus	Deposit Amount Price DepositAmountPrice	10.2
CY2021Q3	oxus	Gross Proceeds Of Warrants GrossProceedsOfWarrants	23400000	usd
CY2021Q3	oxus	Aggregate Proceeds Amount AggregateProceedsAmount	175950000	usd
CY2021Q3	us-gaap	Other Underwriting Expense OtherUnderwritingExpense	450000	usd
CY2022	oxus	Public Per Shares PublicPerShares	10.2
CY2022	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	5000001	usd
CY2022	oxus	Percentage Of Public Shares PercentageOfPublicShares	0.15	pure
CY2022	oxus	Dissolution Expenses DissolutionExpenses	100000	usd
CY2022	oxus	Working Capital WorkingCapital	680000	usd
CY2022	oxus	Opening Bank Account OpeningBankAccount	178530000	usd
CY2022Q4	us-gaap	Assets Held In Trust Current AssetsHeldInTrustCurrent	1580000	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Use of Estimates</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.9pt">The preparation of financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statement, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Estimates made in preparing these financial statements include, among other things, the fair value measurement of shares transferred by the Sponsor to independent director nominees. Actual results could differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.9pt"> </p>
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	680000	usd
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	1120000	usd
CY2022Q4	us-gaap	Assets Held In Trust AssetsHeldInTrust	178530000	usd
CY2021Q4	us-gaap	Assets Held In Trust AssetsHeldInTrust	175950000	usd
CY2022	oxus	Exercise Price ExercisePrice	11.5
CY2022	us-gaap	Gross Profit GrossProfit	175950000	usd
CY2021	us-gaap	Gross Profit GrossProfit	172500000	usd
CY2021	oxus	Proceeds Allocated To Public Warrants ProceedsAllocatedToPublicWarrants	-10522500	usd
CY2021	oxus	Ordinary Shares Issuance Costs OrdinarySharesIssuanceCosts	-3874702	usd
CY2021	oxus	Subtotal Of Ordinary Shares Subject To Possible Redemption SubtotalOfOrdinarySharesSubjectToPossibleRedemption	-14397202	usd
CY2021	us-gaap	Temporary Equity Other Changes TemporaryEquityOtherChanges	17847202	usd
CY2022	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	2582948	usd
CY2022	oxus	Contingently Redeemable Ordinary Shares ContingentlyRedeemableOrdinaryShares	178532948	usd
CY2021	oxus	Contingently Redeemable Ordinary Shares ContingentlyRedeemableOrdinaryShares	175950000	usd
CY2022	oxus	Aggregate Offering Cost AggregateOfferingCost	3870000	usd
CY2022	oxus	Underwriters Commissions UnderwritersCommissions	3450000	usd
CY2022	oxus	Other Offering Costs OtherOfferingCosts	700000	usd
CY2022	oxus	Weighted Average Reduced Shares WeightedAverageReducedShares	1125000	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	562500	shares
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Concentration of Credit Risk</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.9pt">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash accounts in a financial institution which, at times, may exceed the federal depository insurance coverage corporation limit of $250,000. The Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.9pt"> </p>
CY2022	us-gaap	Federal Deposit Insurance Corporation Premium Expense FederalDepositInsuranceCorporationPremiumExpense	250000	usd
CY2021Q3	oxus	Net Proceeds NetProceeds	23400000	usd
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.50	pure
CY2022Q4	us-gaap	Shares Issued SharesIssued	15000000	shares
CY2021Q3	oxus	Aggregate Proceeds Held In Trust Account AggregateProceedsHeldInTrustAccount	175950000	usd
CY2021Q1	oxus	Offering Cost OfferingCost	25000	usd
CY2022	us-gaap	Related Party Transaction Description Of Transaction RelatedPartyTransactionDescriptionOfTransaction	The Founder Shares include an aggregate of up to 1,125,000 Class B ordinary shares subject to forfeiture by the Sponsor to the extent that the underwriters’ over-allotment is not exercised in full or in part, so that the number of Founder Shares will collectively represent 20% of the Company’s issued and outstanding shares upon the completion of the Initial Public Offering.
CY2021Q3	us-gaap	Stock Issued During Period Shares Purchase Of Assets StockIssuedDuringPeriodSharesPurchaseOfAssets	150000	shares
CY2021Q3	oxus	Founder Shares Granted FounderSharesGranted	380000	usd
CY2021Q3	us-gaap	Net Asset Value Per Share NetAssetValuePerShare	2.54
CY2021Q3	us-gaap	Due From Other Related Parties Current DueFromOtherRelatedPartiesCurrent	40	usd
CY2021Q3	oxus	Related Party Outstanding Balance RelatedPartyOutstandingBalance	280000	usd
CY2022	oxus	Working Capital Loans WorkingCapitalLoans	1500000	usd
CY2022Q3	oxus	Promissory Note PromissoryNote	1500000	usd
CY2022Q4	us-gaap	Federal Home Loan Bank Advances Long Term FederalHomeLoanBankAdvancesLongTerm	860000	usd
CY2022	us-gaap	Professional Fees ProfessionalFees	60000.00	usd
CY2022Q4	us-gaap	Other Additional Capital OtherAdditionalCapital	100000	usd
CY2022	us-gaap	Direct Operating Communications Costs DirectOperatingCommunicationsCosts	120000	usd
	us-gaap	Direct Operating Costs DirectOperatingCosts	30000	usd
CY2022	oxus	Description Of Business Combination DescriptionOfBusinessCombination	The Company will pay EarlyBirdCapital and Sova Capital a cash fee for such services upon the consummation of a Business Combination of $4.50 million (or $5.23 million if the underwriters’ over-allotment is exercised in full) that equals to 3.0% of the gross proceeds of Initial Public Offering (exclusive of any applicable finders’ fees which might become payable).
CY2022	us-gaap	Payments For Legal Settlements PaymentsForLegalSettlements	200000	usd
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022	oxus	Preferred Shares Issued Or Outstanding PreferredSharesIssuedOrOutstanding	At December 31, 2022 and December 31, 2021, there were no shares of preferred stock issued or outstanding.
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2022	oxus	Proceeds From Issuance Of Common Stock Sponsor ProceedsFromIssuanceOfCommonStockSponsor		usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2022	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity		usd
CY2022	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement		usd
CY2022	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt		usd
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts		usd
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations		usd
CY2022	oxus	Deferred Offering Costs Included In Accrued Expenses DeferredOfferingCostsIncludedInAccruedExpenses		usd
CY2022	oxus	Issuance Of Underwriter Founder Shares IssuanceOfUnderwriterFounderShares		usd
	oxus	Remeasurement For Class A Ordinary Shares Subject To Redemption RemeasurementForClassAOrdinarySharesSubjectToRedemption		usd
CY2022	oxus	Proceeds Allocated To Public Warrants ProceedsAllocatedToPublicWarrants		usd
CY2022	oxus	Ordinary Shares Issuance Costs OrdinarySharesIssuanceCosts		usd
CY2022	oxus	Warrants For Redemption Description WarrantsForRedemptionDescription	Public Warrants may only be exercised for a whole number of shares. No fractional shares will be issued upon exercise of the Public Warrants. The Public Warrants will become exercisable on the later of (a) 30 days after the completion of a Business Combination and (b) 12 months from the closing of the Initial Public Offering. Redemption of Warrants When the Price per Share of Class A Ordinary shares Equals or Exceeds $18.00 —once the warrants become exercisable, the Company may redeem the outstanding Public Warrants: ●in whole and not in part; ●at a price of $0.01 per Public Warrant; ●upon not less than 30 days’ prior written notice of redemption to each warrant holder; and ●if, and only if, the last reported sale price of the Class A ordinary shares for any 20 trading days within a 30 trading day period ending three business days before sending the notice of redemption to warrant holders (the “Reference Value”) equals or exceeds $18.00 per share (as adjusted for stock splits, stock capitalizations, reorganizations, recapitalizations and the like).
CY2021Q3	oxus	Over Allotment Liability OverAllotmentLiability	297073	usd
CY2021Q3	oxus	Initial Measurement Of Overallotment Option InitialMeasurementOfOverallotmentOption	297073	usd
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease	-16788	usd
CY2021Q4	oxus	Overallotment Options OverallotmentOptions	-280285	usd
CY2022	us-gaap	Debt Conversion Description DebtConversionDescription	i) the lesser of (a) an aggregate of $180,000 or (b) $0.12 per public share that remain outstanding and is not redeemed in connection with the Extension plus (ii) the lesser of (a) an aggregate of $60,000 or (b) $0.04 per public share that remain outstanding and is not redeemed in connection with the Extension for each of the six subsequent calendar months commencing on June 8, 2023 (the “Extension Loan”), which amount will be deposited into the Trust Account. On March 3, 2023, the Sponsor funded $200,000 through the Amended Note, out of which $180,000 was deposited into the Trust Account as the initial deposit of the Extension Loan.
CY2021Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent		usd
CY2021Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax		usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity		usd
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized		usd
CY2022	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities		usd
	oxus	Increase Decrease In Prepaid Expenses Other Non Current IncreaseDecreaseInPrepaidExpensesOtherNonCurrent		usd
CY2022	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments		usd
CY2022	oxus	Subtotal Of Ordinary Shares Subject To Possible Redemption SubtotalOfOrdinarySharesSubjectToPossibleRedemption		usd
CY2021	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue		usd
CY2021Q1	oxus	Overallotment Options OverallotmentOptions		usd
CY2021	oxus	Overallotment Option OverallotmentOption		usd
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001852973

Files In Submission

Name	View Source	Status
0001213900-23-025396-index-headers.html	Edgar Link	pending
0001213900-23-025396-index.html	Edgar Link	pending
0001213900-23-025396.txt	Edgar Link	pending
0001213900-23-025396-xbrl.zip	Edgar Link	pending
f10k2022ex31-1_oxusacq.htm	Edgar Link	pending
f10k2022ex31-2_oxusacq.htm	Edgar Link	pending
f10k2022ex32-1_oxusacq.htm	Edgar Link	pending
f10k2022_oxusacq.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
oxus-20221231.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
oxus-20221231_cal.xml	Edgar Link	unprocessable
oxus-20221231_def.xml	Edgar Link	unprocessable
oxus-20221231_lab.xml	Edgar Link	unprocessable
oxus-20221231_pre.xml	Edgar Link	unprocessable
f10k2022_oxusacq_htm.xml	Edgar Link	completed
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BRLS
Borealis Foods Inc. Stock $brls

2022 Q4 Form 10-K Financial Statement

#000121390023025396 Filed on March 31, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BRLS Borealis Foods Inc. Stock $brls

2022 Q4 Form 10-K Financial Statement

#000121390023025396 Filed on March 31, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BRLS
Borealis Foods Inc. Stock $brls